By Patrick Thomas

AstraZeneca PLC (AZN, AZN.LN) said Wednesday that a phase 3 trial for its triple-combination therapy PT010 in patients with chronic obstructive pulmonary disease met primary endpoints.

The drugmaker said that PT010, a combination of budesonide, glycopyrronium, formoterol fumarate, demonstrated significant reduction in the rate of moderate or severe exacerbations compared with dual-combination therapies of glycopyrronium and formoterol fumarate.

Exacerbations in patients and can lead to a permanent loss of lung function. PT010 has been approved in Japan and is under regulatory review in China as well as Europe.

"The Phase III ETHOS trial results are exciting and demonstrate that PT010 significantly reduces the rate of exacerbations," the lead investigator of the phase 3 Ethos trial said in a statement.

The company said the Ethos trial results will be presented at an upcoming medical meeting.

Write to Patrick Thomas at patrick.thomas@wsj.com

(END) Dow Jones Newswires

August 28, 2019 08:08 ET (12:08 GMT)

Copyright (c) 2019 Dow Jones & Company, Inc.
Grafico Azioni Astrazeneca (LSE:AZN)
Storico
Da Mar 2024 a Apr 2024 Clicca qui per i Grafici di Astrazeneca
Grafico Azioni Astrazeneca (LSE:AZN)
Storico
Da Apr 2023 a Apr 2024 Clicca qui per i Grafici di Astrazeneca